Clinical and biomarker characteristics of Huntington’s Disease patients recently proposed for huntingtin-lowering clinical trial inclusion
Objective: We investigated plasma NfL levels, as well as clinical measures, in Huntingtin (Htt)-mutation carriers 48 years of age and under, with a CAP score…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Contemporary study of the difficulties of late diagnostics in patients with Huntington’s disease in Uzbekistan
Objective: To identify the causes that lead to late diagnosis of Huntington's disease. Background: Huntington's disease is a rare, progressive, and fatal autosomal dominant neurodegenerative…A randomized, sham-controlled, crossover trial on Transcranial pulsed current stimulation (tPCS) in Huntington disease
Objective: 1. To assess brain network level dysfunction of Huntington disease (HD). 2. To evaluate the effectiveness of 2-week home-based chronic non-invasive transcranial brain stimulation (NIBS) in…Reversible hemichorea due to contralateral anterior cerebral artery territory hypoperfusion
Objective: We report hemichorea due to hypoperfusion of the contralateral anterior cerebral artery (ACA) territory (including caudate nucleus and its connections) that reversed with revascularization.…Medically refractory Graves’ disease presenting as chorea and carbohydrate hyperphagia in a Kenyan adolescent
Objective: To report a unique case of adolescent-onset autoimmune hyperthyroidism presenting with chorea and carbohydrate hyperphagia (CH). Background: Autoimmune hyperthyroidism [Graves’ disease (GD)] can cause…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…Diabetes Mellitus in Huntington’s disease. The Argentinean perspective
Objective: to compare the prevalence of diabetes mellitus (DM) in a self-reported series of local Huntington disease (HD) participants in the ENROLL-HD registry with the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »